Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
DaVita operates 2,800+ outpatient dialysis centers across the U.S., treating ~200,000 patients with end-stage renal disease (ESRD). The company generates revenue primarily through Medicare/Medicaid reimbursement (~75% of revenue) and commercial insurance (~25%), with profitability heavily dependent on government payment rates and patient mix. DaVita is the second-largest dialysis provider in the U.S. after Fresenius Medical Care.
DaVita operates a high-volume, low-margin business model where patients receive dialysis treatments 3x per week. Revenue per treatment averages $350-400 for commercial payers (generating 3-4x Medicare rates) versus $230-250 for Medicare/Medicaid. Profitability depends on: (1) maximizing commercial patient mix (currently ~10-12% of patients generating ~25% of revenue), (2) managing labor costs (50-55% of operating expenses), (3) pharmaceutical cost management (EPO, iron, calcimimetics), and (4) treatment efficiency across centers. The company has pricing power with commercial insurers due to network necessity but faces regulatory risk on Medicare rates (updated annually via ESRD PPS). Operating leverage is moderate - high fixed costs (facility leases, equipment) but variable labor scheduling provides some flexibility.
Medicare reimbursement rate changes: Annual ESRD PPS updates (typically 0-2% increases, but cuts possible) directly impact 75% of revenue
Commercial rate environment: Ability to maintain $350-400/treatment rates versus Medicare's $230-250 baseline; commercial mix percentage
Patient census growth: Organic growth of 1-2% annually driven by diabetes/hypertension prevalence; acquisition activity
Labor cost inflation: Wage pressure for nurses and patient care technicians (50-55% of opex); turnover rates and staffing challenges
Regulatory/legislative risk: Potential Medicare Advantage rate changes, state-level dialysis ballot initiatives (California Prop 29), or federal payment reforms
Medicare reimbursement pressure: CMS rate cuts or payment model changes (bundled payments, value-based care) could compress margins; 75% revenue exposure to government payers creates policy risk
Regulatory intervention: State-level ballot initiatives (California Prop 29 attempted to cap profits), potential federal price controls, or increased quality reporting requirements
Home dialysis shift: Growing adoption of home hemodialysis and peritoneal dialysis (currently ~15% of patients) could disrupt center-based model, though DaVita is investing in home programs
Labor market structural tightness: Chronic nursing shortages and wage inflation in healthcare sector
Fresenius Medical Care dominance: Larger competitor with ~40% U.S. market share versus DaVita's ~35%; potential for pricing pressure or market share loss
Hospital-based dialysis competition: Health systems developing in-house dialysis programs to capture economics, particularly for commercially insured patients
Vertical integration by payers: Risk of Medicare Advantage plans or commercial insurers developing owned dialysis capacity to control costs
High leverage: $8-9B debt with 3.5-4.0x Net Debt/EBITDA; refinancing risk if credit markets tighten or if EBITDA declines from rate cuts
Negative equity position: Aggressive share repurchases and debt-financed M&A have created -$23 Debt/Equity ratio; limits financial flexibility
Legal/regulatory settlements: Ongoing DOJ investigations, qui tam lawsuits, and potential fines create contingent liability risk
low - ESRD dialysis is non-discretionary medical care with minimal GDP sensitivity. Patient volumes are driven by chronic disease prevalence (diabetes, hypertension) rather than economic cycles. However, commercial insurance coverage is tied to employment levels, so recessions can shift payer mix unfavorably from commercial to Medicare/Medicaid, compressing margins by 200-300 bps.
moderate - DaVita carries $8-9B in debt (Debt/EBITDA ~3.5-4.0x) with a mix of fixed and floating rate obligations. Rising rates increase interest expense on floating debt and refinancing costs, directly impacting net income. Additionally, higher rates compress valuation multiples for cash flow-oriented healthcare stocks. Each 100 bps rate increase adds ~$30-40M in annual interest expense on floating portions.
moderate - While dialysis services are non-discretionary, the company faces credit risk from: (1) patient co-pays and deductibles (bad debt typically 1-2% of revenue), (2) commercial insurer payment disputes and denials, and (3) tightening credit conditions that could limit M&A financing or refinancing flexibility. Economic downturns increase uninsured/underinsured patient populations, pressuring collections.
value - Stock trades at 0.8x P/S and 9.4x EV/EBITDA with 12.5% FCF yield, attracting value investors focused on cash generation and capital returns. The company returns substantial capital via buybacks ($800M-1.2B annually). However, regulatory overhang and negative equity deter growth investors. Suitable for investors comfortable with healthcare policy risk and leveraged balance sheets.
moderate-to-high - Stock exhibits elevated volatility around Medicare rate announcements, earnings releases, and regulatory events (ballot initiatives, DOJ investigations). Beta typically 1.1-1.3x. Recent 3-month surge of 20% followed by 1-year decline of -16.6% reflects sentiment swings on policy developments and earnings variability.
